A new combination therapy regimen shows promising results for prostate cancer
TALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.
Mar 17, 2023
0
6